Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the antiviral efficacy, safety, and tolerability of
ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with nosocomial
genotype 1 hepatitis C virus (HCV) infection.
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Ledipasvir Ledipasvir, sofosbuvir drug combination Sofosbuvir